Daruka Mahadevan, MD, PhD

Therapeutic Development Program co-Leader
Therapeutic Development Program, Research Member

Biography

Dr. Mahadevan is a Professor of Medicine and a recognized expert and highly experienced Physician-Scientist in Hematology and Oncology, and currently the Director of the Early Phase Clinical Trials Program and Co-Director of Experimental Therapeutics at the University of Arizona – Arizona Cancer Center. He received his medical degree from the University of London, England, UK. He is certified by the American Board of Internal Medicine, subspecialty of Medical Oncology.

Dr. Mahadevan’s major area of clinical interest is in the treatment and management of patients with pancreatic cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non-Hodgkin’s lymphoma (NHL) including Chronic Lymphocytic Leukemia (CLL).

Cancer Focus

Dr. Mahadevan has a demonstrated track record of delivering first-in-human investigational agents for all oncology therapeutics. In addition, he has successfully directed a structure-based translational drug discovery laboratory program with the award of 6 US patents for new drugs targeting novel driver oncogenes. As PI or Co-PI on several NIH and Foundation grants, he established proof-of-concept and delivered on drug discovery - R01 (AKT PH domain inhibitors) and on drug development - NSF (Prostate cancer translational drug development), SPORE in Lymphoma (Aurora kinase inhibitor therapy for aggressive lymphoma) and SWOG Hope Foundation (targeted therapeutics for aggressive B-cell non-Hodgkin Lymphomas).